The Online Investor
Auxilium Pharmaceuticals Inc (AUXL)

Auxilium Pharmaceuticals is a biopharmaceutical company with a focus on developing and commercializing products for specialist audiences. Co. has a range of first- and second-line products across multiple indications, including men's healthcare, orthopedics, dermatology and other therapeutic areas. Among other products in the U.S., Co. markets Testim® (testosterone gel) for the topical treatment of hypogonadism; TESTOPEL® (testosterone pellets) a long-acting implantable testosterone replacement therapy product; STENDRA™ (avanafil), an oral erectile dysfunction (ED) therapy; as well as Edex® (alprostadil for injection), an injectable treatment for ED.
Company Name: 
Auxilium Pharmaceuticals Inc
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree AUXL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Auxilium Pharmaceuticals Inc (AUXL) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.